Health Condition 1: K742- Hepatic fibrosis with hepatic sclerosis
Conditions
Interventions
Intervention1: DAPAGLIFLOZIN and PIOGLITAZONE: patients of non alcoholic fatty live disease with type 2 diabetes will be divided into 3 groups by randomisation. After randomisation, one study group w
Sponsors
BOLISETTY TULASI DEVI
Eligibility
Inclusion criteria
Inclusion criteria: presence of fatty liver on ultrasound with deranged liver enzymes who are known cases of non alcoholic fatty liver disease spectrum with type 2DM and HbA1c of more than 6.5
Exclusion criteria
Exclusion criteria: patients of chronic or viral hepatitis B or C infection, significant alcohol intake of more than 30g in males and 20g per day in females after converting to ethanol, cases with history of hepatotoxic drugs, drugs leading to hepatic fibrosis or drugs supposed to decrease hepatic fibrosis like omega 3 fatty acids, vitamin E, UDCA, saroglitazar, pioglitazone, GLP1 agonists, documented cases of autoimmune hepatitis, hepatic storage or hereditary diseases, Wilsons, hemochromatosis will be excluded. patients with severe renal dysfunction, ischemic heart disease, heart failure with NYHA grade 3 at present or past, complicated UTI or pyelonephritis, Pregnant and lactating females will be excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver stiffness measurement score by Transient elastography, SGOT, SGPT, TPC, APRI, FIB 4, NAFLD FIBROSIS SCORETimepoint: once before initiating the drug and once after completion of 3 months course | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1cTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Bolisetty Tulasi Devi
IMS AND SUM HOSPITAL
Outcome results
None listed